These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37805405)

  • 1. [Primary DEK::AFF2 fusion positive nonkeratinizing squamous cell carcinoma of the middle ear: report of a case].
    Yu ST; Ye XZ; Xu BQ; Ouyang XJ; Zhang JQ; Qu LJ
    Zhonghua Bing Li Xue Za Zhi; 2023 Oct; 52(10):1058-1060. PubMed ID: 37805405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Middle Ear and Temporal Bone Nonkeratinizing Squamous Cell Carcinomas With DEK-AFF2 Fusion: An Emerging Entity.
    Todorovic E; Truong T; Eskander A; Lin V; Swanson D; Dickson BC; Weinreb I
    Am J Surg Pathol; 2020 Sep; 44(9):1244-1250. PubMed ID: 32366754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DEK-AFF2 fusion-associated papillary squamous cell carcinoma of the sinonasal tract: clinicopathologic characterization of seven cases with deceptively bland morphology.
    Kuo YJ; Lewis JS; Zhai C; Chen YA; Chernock RD; Hsieh MS; Lan MY; Lee CK; Weinreb I; Hang JF
    Mod Pathol; 2021 Oct; 34(10):1820-1830. PubMed ID: 34108636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonkeratinizing Squamous Cell Carcinoma of the Sinonasal Tract With DEK-AFF2: Further Solidifying an Emerging Entity.
    Bishop JA; Gagan J; Paterson C; McLellan D; Sandison A
    Am J Surg Pathol; 2021 May; 45(5):718-720. PubMed ID: 33002918
    [No Abstract]   [Full Text] [Related]  

  • 5. DEK::AFF2 Fusion Carcinomas of Head and Neck.
    Ruangritchankul K; Sandison A
    Adv Anat Pathol; 2023 Mar; 30(2):86-94. PubMed ID: 36221219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First Report of Thoracic Carcinoma With DEK::AFF2 Rearrangement: A Case Report.
    Savari O; Chang JC; Bishop JA; Sakthivel MK; Askin FB; Rekhtman N
    J Thorac Oncol; 2022 Aug; 17(8):1050-1053. PubMed ID: 35773081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DEK::AFF2 Fusion-Associated Squamous Cell Carcinoma: A Case Series with Literature Review on an Emerging and Challenging Entity.
    Amin SE; Lewis JS; Bridge JA; Hang JF; Naik U; Bishop JA; Saluja K
    Head Neck Pathol; 2024 Sep; 18(1):86. PubMed ID: 39312022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DEK-AFF2 Carcinoma of the Sinonasal Region and Skull Base: Detailed Clinicopathologic Characterization of a Distinctive Entity.
    Rooper LM; Agaimy A; Dickson BC; Dueber JC; Eberhart CG; Gagan J; Hartmann A; Khararjian A; London NR; MacMillan CM; Palsgrove DN; Nix JS; Sandison A; Stoehr R; Truong T; Weinreb I; Bishop JA
    Am J Surg Pathol; 2021 Dec; 45(12):1682-1693. PubMed ID: 34049316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the DEK oncogene in the development of squamous cell carcinoma.
    Ishida K; Nakashima T; Shibata T; Hara A; Tomita H
    Int J Clin Oncol; 2020 Sep; 25(9):1563-1569. PubMed ID: 32656741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear expression of AFF2 C-terminus is a sensitive and specific ancillary marker for DEK::AFF2 carcinoma of the sinonasal tract.
    Kuo YJ; Lewis JS; Truong T; Yeh YC; Chernock RD; Zhai C; Chen YA; Hongo T; Lee CK; Shi Q; Velez Torres JM; Geromes AB; Chu YH; Hsieh MS; Yamamoto H; Weinreb I; Hang JF
    Mod Pathol; 2022 Nov; 35(11):1587-1595. PubMed ID: 35701667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unclassified Neuroendocrine Tumor with a Novel CHD4::AFF2 Fusion: Expanding the Family of AFF2-Rearranged Head and Neck Malignancies.
    Miller DL; Palsgrove DN; Rijal A; Hathuc V; Chernock R; Gagan J; Bishop JA
    Head Neck Pathol; 2022 Sep; 16(3):928-933. PubMed ID: 35218513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A diagnostic algorithm for sinonasal papillary non-keratinizing squamous cell carcinoma with DEK::AFF2 fusion and mimickers.
    Laforga JB; Othman BK
    Rev Esp Patol; 2024; 57(1):67-70. PubMed ID: 38246714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promotion of cell proliferation by the proto-oncogene DEK enhances oral squamous cell carcinogenesis through field cancerization.
    Nakashima T; Tomita H; Hirata A; Ishida K; Hisamatsu K; Hatano Y; Kanayama T; Niwa A; Noguchi K; Kato K; Miyazaki T; Tanaka T; Shibata T; Hara A
    Cancer Med; 2017 Oct; 6(10):2424-2439. PubMed ID: 28834425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The First Report of Cytology of DEK::AFF2 Fusion-Associated Papillary Squamous Cell Carcinoma on Fine-Needle Aspiration.
    Li JJX; Ng JKM; Chan ABW
    Head Neck Pathol; 2023 Dec; 17(4):1058-1063. PubMed ID: 37938508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and interpretation of AFF immunostain of DEK::AFF2 fusion-associated papillary squamous cell carcinoma in a retrospective cohort of recurrent sinonasal papillomas.
    Ng JKM; Chow C; Tang CY; Chan AZ; Li JJX; Chan ABW
    Virchows Arch; 2024 Jan; 484(1):119-125. PubMed ID: 38063896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DEK proto-oncogene expression interferes with the normal epithelial differentiation program.
    Wise-Draper TM; Morreale RJ; Morris TA; Mintz-Cole RA; Hoskins EE; Balsitis SJ; Husseinzadeh N; Witte DP; Wikenheiser-Brokamp KA; Lambert PF; Wells SI
    Am J Pathol; 2009 Jan; 174(1):71-81. PubMed ID: 19036808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IRAK1 is a novel DEK transcriptional target and is essential for head and neck cancer cell survival.
    Adams AK; Bolanos LC; Dexheimer PJ; Karns RA; Aronow BJ; Komurov K; Jegga AG; Casper KA; Patil YJ; Wilson KM; Starczynowski DT; Wells SI
    Oncotarget; 2015 Dec; 6(41):43395-407. PubMed ID: 26527316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Relationship between DEK oncogene expression and oral squamous cell carcinoma].
    Wang X; Huang SH; Yu LQ; Liu J; Diao Y; Sun CF
    Shanghai Kou Qiang Yi Xue; 2014 Feb; 23(1):75-9. PubMed ID: 24608617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The oncoprotein DEK affects the outcome of PARP1/2 inhibition during mild replication stress.
    Ganz M; Vogel C; Czada C; Jörke V; Gwosch EC; Kleiner R; Pierzynska-Mach A; Zanacchi FC; Diaspro A; Kappes F; Bürkle A; Ferrando-May E
    PLoS One; 2019; 14(8):e0213130. PubMed ID: 31408463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-grade papillary Schneiderian carcinoma with TP53 mutation: a case report and review of the literature.
    Yuzawa S; Michizuka T; Kakisaka R; Ono Y; Hayashi M; Takahara M; Katada A; Mizukami Y; Tanino M
    Diagn Pathol; 2023 Apr; 18(1):44. PubMed ID: 37041626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.